# EDGAR Filing Document

**Accession Number:** 0001610820
**File Stem:** 0001493152-26-002103
**Filing Date:** 2026-1
**Character Count:** 26749
**Document Hash:** 0981a10351779d4369d6602b9ee673cd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-002103.hdr.sgml**: 20260113

**ACCESSION NUMBER**: 0001493152-26-002103

**CONFORMED SUBMISSION TYPE**: S-1MEF

**PUBLIC DOCUMENT COUNT**: 17

**FILED AS OF DATE**: 20260113

**DATE AS OF CHANGE**: 20260113

**EFFECTIVENESS DATE**: 20260113

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BriaCell Therapeutics Corp.
- **CENTRAL INDEX KEY:** 0001610820
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 0731

**FILING VALUES:**
- **FORM TYPE:** S-1MEF
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-292716
- **FILM NUMBER:** 26531299

**BUSINESS ADDRESS:**
- **STREET 1:** 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR
- **CITY:** WEST VANCOUVER
- **STATE:** A1
- **ZIP:** V7T 2X1
- **BUSINESS PHONE:** (604) 921-1810

**MAIL ADDRESS:**
- **STREET 1:** 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR
- **CITY:** WEST VANCOUVER
- **STATE:** A1
- **ZIP:** V7T 2X1

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Ansell Capital Corp.
- **DATE OF NAME CHANGE:** 20140613

**As filed with the Securities and Exchange Commission on January 13, 2026**

**Registration No. 333-** 

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-1**

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933**

**<u>BRIACELL THERAPEUTICS CORP.</u>**

(Exact name of Registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **British Columbia** | **2834** | **47-1099599** |
| (State or other jurisdiction of <br> incorporation or organization) | (Primary standard industrial <br> classification code number) | (I.R.S. employer <br> identification number) |

---

**Suite 300 - 235 15th Street**

**West Vancouver, BC V7T 2X1**

**(604) 921-1810**

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

**Dr. William V. Williams**

**Chief Executive Officer**

**Suite 300 - 235 15th Street**

**West Vancouver, BC V7T 2X1, Canada**

**(604) 921-1810**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

---

| | |
|:---|:---|
| **Gregory Sichenzia, Esq.**<br> **Avital Perlman, Esq.**<br> **Sichenzia Ross Ference Carmel LLP**<br> **1185 Avenue of the Americas, 31<sup>st</sup> Floor**<br> **New York, NY 10036**<br> **Telephone: (212) 930-9700** | **Virgil Hlus, Esq.**<br> **Andrew Stewart, Esq.**<br> **Cozen O'Connor LLP**<br> **Bentall 5, 550 Burrard Street, Suite 2501**<br> **Vancouver, BC V6C 2B5, Canada**<br> **Telephone: (604) 674-9170** |

---

Approximate date of commencement of proposed sale to the public: As soon as practicable after this Registration Statement becomes effective.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒ 333-292388

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**This Registration Statement shall become effective upon filing with the Securities and Exchange Commission in accordance with Rule 462(b) of the Securities Act of 1933, as amended.**

**EXPLANATORY NOTE**

BriaCell Therapeutics Corp. (the "Company") is filing this Registration Statement on Form S-1 (the "Registration Statement") with the Securities and Exchange Commission ("SEC") pursuant to Rule 462(b) of the Securities Act of 1933, as amended. The contents of the Registration Statement on Form S-1 (File No. 333-292388) filed by the Company with the SEC on December 23, 2025, including the exhibits thereto, are incorporated herein by reference.

We are filing this Registration Statement for the purpose of registering additional securities of the Company with the proposed maximum aggregate offering price not to exceed $11,562,500.

The required opinions and consents are listed on an Exhibit Index attached hereto and filed herewith.

---

| | |
|:---|:---|
| **Exhibit**<br> **Number** | **Description** |
| 5.1 | [Opinion of Bennett Jones LLP](ex5-1.htm) |
| 5.2 | [Opinion of Sichenzia Ross Ference Carmel LLP](ex5-2.htm) |
| 23.1 | [Consent of MNP LLP](ex23-1.htm) |
| 23.2 | [Consent of Bennett Jones LLP (included in Exhibit 5.1)](ex5-1.htm) |
| 23.3 | [Consent of Sichenzia Ross Ference Carmel LLP (included in Exhibit 5.2)](ex5-2.htm) |
| 107 | [Filing Fee Table](ex107.htm) |

---

**Signatures**

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in West Vancouver, British Columbia on January 13, 2026.

---

| | |
|:---|:---|
| **BRIACELL THERAPEUTICS CORP.** | **BRIACELL THERAPEUTICS CORP.** |
| (Registrant) | (Registrant) |
| By: | */s/ William V. Williams* |
|  | Dr. William V. Williams |
|  | President, Chief Executive Officer and Chairman |
|  | (Principal Executive Officer) |
| By: | */s/ Gadi Levin* |
|  | Gadi Levin |
|  | Chief Financial Officer |
|  | (Principal Financial and Accounting Officer) |

---

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated:

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| */s/ Dr. William V. Williams* | President, Chief Executive Officer and Chairman | January 13, 2026 |
| Dr. William V. Williams | (Principal Executive Officer) |  |
| */s/ Gadi Levin* | Chief Financial Officer | January 13, 2026 |
| Gadi Levin | (Principal Financial and Accounting Officer) |  |
| */s/ Jamieson Bondarenko* | Chairman, Director | January 13, 2026 |
| Jamieson Bondarenko |  |  |
| */s/ Dr. Rebecca Taub* | Director | January 13, 2026 |
| Dr. Rebecca Taub |  |  |
| */s/ Vaughn C. Embro-Pantalony* | Director | January 13, 2026 |
| Vaughn C. Embro-Pantalony |  |  |
| */s/ Martin Schmieg* | Director | January 13, 2026 |
| Martin Schmieg |  |  |
| */s/ Dr. Jane Gross* | Director | January 13, 2026 |
| Dr. Jane Gross |  |  |

---

## Exhibit 5.1

**Exhibit 5.1**

![](ex5-1_001.jpg)

January 13, 2026

BriaCell Therapeutics Corp.

Suite 300 – 235 15th Street

West Vancouver, British Columbia

Canada V7T 2X1

**Re: Registration Statement on Form S-1 Filed Pursuant to Rule 462(b)**

Ladies and Gentlemen:

We have acted as special Canadian legal counsel to BriaCell Therapeutics Corp., a British Columbia corporation (the "**Company**"), in connection with the Company's registration statement on Form S-1 (the "**462(b) Registration Statement**") filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the "**Act**"), filed the Securities and Exchange Commission (the "**Commission**"), which incorporates by reference the Registration Statement on Form S-1 (File No. 333-292388) (including the prospectus filed therewith, the "**Prospectus**"), which was declared effective on January 13, 2026 (the "**Initial Registration Statement**" and, together with the 462(b) Registration Statement, the "**Registration Statement**").

This opinion is furnished to you in connection with your filing of the 462(b) Registration Statement, which is registering the offering by the Company of: (i) (A) Common Units, with each Common Unit consisting of (I) one common share (the "**Common Unit Shares**") and (II) one warrant (the "**Warrants**") entitling the holder to purchase one common share (the "**Warrant Shares**") and/or (B) pre-funded units (the "**Pre-funded Units**") consisting of (I) one pre-funded warrant (the "**Pre-funded Warrant**") to purchase one common share (the "**Pre-funded Warrant Shares**") and (II) one Warrant; (ii) Pre-funded Warrant Shares; (iii) Warrant Shares; (iv) Placement Agent Warrants (defined below) and (v) Placement Agent Warrant Shares (defined below) (collectively, the "**Offered Securities**").

We understand that the Common Units, the Pre-funded Units, and the underlying shares and warrants, are to be sold by the Company to the public as described in the Registration Statement and pursuant to a placement agency agreement to be entered into by and among the Company and ThinkEquity LLC (the "**Placement Agent**"), substantially in the form filed as an exhibit to the Initial Registration Statement (together with all schedules, exhibits and ancillary documents and agreements thereto, the "**Placement Agency Agreement**"). The Common Units and Pre-funded Units, and the underlying shares and warrants, are being registered by the Company in connection with a public offering of the Company (the "**Offering**"). The offering prices of the Common Units and Pre-funded Units are to be determined by the Company and the investors in the Offering.

Pursuant to the Placement Agency Agreement the Company agrees to issue to the Placement Agent, as partial compensation for its services, certain common share purchase warrants equal to 3.0% of the aggregate number of Common Units and Pre-funded Units (each, a "**Placement Agent Warrant**"). Each Placement Agent Warrant will entitle the holder to purchase one common share of the Company (each, a "**Placement Agent Warrant Share**") for a period of five years from the effective date of the Registration Statement (the "**Effective Date**") at a price per Placement Agent Warrant Share equal to 150% of the final public offering price of the Common Units sold in the Offering.

In connection with this opinion, we have reviewed and relied upon originals, photocopies or copies, certified or otherwise identified to our satisfaction, of the Registration Statement and Prospectus, the Company's Notice of Articles, the Company's Articles, records of the Company's corporate proceedings in connection with the Offering, and such other documents, records, certificates, memoranda and other instruments as we deem necessary as a basis for this opinion. With respect to the foregoing documents, we have assumed, without independent investigation: (i) the authenticity of all records, documents, and instruments submitted to us as originals; (ii) the genuineness of all signatures on all agreements, instruments and other documents submitted to us; (iii) the legal capacity and authority of all persons or entities (other than the Company) executing all agreements, instruments or other documents submitted to us; (iv) the authenticity and the conformity to the originals of all records, documents, and instruments submitted to us as copies; (v) that the statements contained in the certificates and comparable documents of public officials, officers and representatives of the Company and other persons on which we have relied for purposes of this opinion are true and correct; and (vi) that the Registration Statement has been declared effective pursuant to the Act. We have also obtained from officers of the Company certificates as to certain factual matters and, insofar as this opinion is based on matters of fact, we have relied on such certificates without independent investigation. With respect to the Placement Agency Agreement and the Warrants, the Pre-funded Warrants and the Placement Agent Warrants, all of which are governed by and construed in accordance with the laws of the State of New York, we have assumed that these agreements comply with and do not violate the laws of the State of New York.

Our opinion is limited to laws of the Province of British Columbia. We have not considered, and have not expressed any opinion with regard to, or as to the effect of, any other law, rule, or regulation, state or federal, applicable to the Company. In particular, we express no opinion as to United States federal securities laws.

Based upon the foregoing and in reliance thereon, and subject to the qualifications and limitations set forth herein, we are of the opinion that:

&nbsp;&nbsp;&nbsp;&nbsp;1. Upon
 payment to the Company of the consideration per Common Unit and Pre-funded Unit, as applicable, in such amount and form as shall
 be determined by the board of directors of the Company (the "**Board**") or the persons authorized by the Board, the
 issuance and sale of the Common Units, Pre-funded Units, Common Unit Shares, Pre-funded Warrants, Warrants and the Placement Agent
 Warrants in the manner and under the terms described in the Registration Statement have been duly authorized by all necessary corporate
 action by the Company and the Common Unit Shares will be validly issued, fully paid and non-assessable shares in the capital of the
 Company; and

2. The
 Warrant Shares, the Pre-funded Warrant Shares and Placement Agent Warrant Shares have been duly authorized by all necessary corporate
 action and, when issued and delivered by the Company in receipt for the exercise price therefor in the manner contemplated in the
 Registration Statement and the Warrants, Pre-funded Warrants and Placement Agent Warrants, will be validly issued, fully paid and
 non-assessable shares in the capital of the Company.

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the use of our firm's name in the section of the Registration Statement and the Prospectus included therein entitled "Legal Matters". In giving this consent, we do not admit that we are within the category of persons whose consent is required under Section 7 of the Act, or the rules and regulations of the Commission.

This opinion is limited to the specific issues addressed herein, and no opinion may be inferred or implied beyond that expressly stated herein. We disclaim any obligation to advise you of facts, circumstances, events or developments that hereafter may be brought to our attention and that may alter, affect or modify the opinion expressed herein after the effective date of the Registration Statement.

---

| |
|:---|
| Yours truly, |
| */s/ Bennett Jones* |

---

## Exhibit 5.2

**Exhibit 5.2**

![](ex5-2_001.jpg)

January 13, 2026

BriaCell Therapeutics Corp.

Suite 300, 235 15<sup>th</sup> Street

West Vancouver, BC V7T 2X1

Ladies and Gentlemen:

We have acted as U.S. counsel to BriaCell Therapeutics Corp., a corporation organized under the laws of the Province of British Columbia (the "Company"). This opinion is furnished to you in connection with the Registration Statement on Form S-1 (such registration statement, as amended through the date hereof, the "Registration Statement") and the prospectus forming part of the registration statement ("Prospectus") filed by the Company with the Securities and Exchange Commission (the "Commission") under the Securities Act of 1933, as amended (the "Securities Act"), relating to the proposed offer and sale by the Company (the "Offering") of (i) units (the "Units"), with each Unit consisting of (a) one common share and (b) one warrant to purchase one common share (the "Warrants"), (ii) pre-funded units (the "Pre-funded Units"), with each Pre-funded Unit consisting of (a) one pre-funded warrant to purchase one common share (the "Pre-funded Warrants") and (b) one Warrant, and (iii) Warrants to purchase a number of common shares equal to 3% of the aggregate number of common shares and Pre-funded Warrants (the "Placement Agent Warrants" and, together with the Units, the Pre-funded Units, the Warrants, the Pre-funded Warrants and the common shares included in the Units and underlying the Warrants and Pre-Funded Warrants, the "Securities") issuable to the Placement Agent (as defined below). The Company shall engage ThinkEquity LLC to act as the placement agent (the "Placement Agent") in this offering pursuant to the terms of a placement agency agreement (the "Placement Agency Agreement").

This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or the Prospectus that is a part of the Registration Statement, other than as expressly stated herein.

In connection with this opinion, we have examined originals or copies, certified or otherwise identified to our satisfaction, of such records of the Company and such agreements, certificates and statements of public officials, certificates of officers or representatives of the Company, and such other documents, certificates and records as we have deemed necessary or appropriate as a basis for the opinion set forth herein. In our examination, we have assumed the legal capacity of all natural persons, the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified or photostatic copies and the authenticity of all originals of such latter documents. In making our examination of the documents executed by the parties, we have assumed that such parties had the power, corporate or other, to enter into and perform all obligations thereunder and have also assumed the due authorization by all requisite action, corporate or other, and execution and delivery by such parties of such documents and the validity and binding effect thereof. In addition, we have assumed that when issued and paid for pursuant to the Placement Agency Agreement and the Prospectus, the Securities will be validly issued, fully paid and non-assessable. Except as expressly set forth herein, we have not undertaken any independent investigation to determine the existence or absence of facts material to the opinions expressed herein and no inference as to our knowledge concerning such facts should be drawn from the fact that such representation has been relied upon by us in connection with the preparation and delivery of this opinion. As to any facts material to the opinions expressed herein which were not independently established or verified, we have relied upon oral or written statements and representations of officers and other representatives of the Company and others, including those set forth in the Placement Agency Agreement.

1185 AVENUE OF THE AMERICAS \| 31ST FLOOR \| NEW YORK, NY \| 10036<br>T (212) 930-9700 \| F (212) 930-9725 \| WWW.SRFC.LAW<br>

We are admitted to the Bar in the State of New York. We express no opinion as to the laws of any jurisdiction other than the laws of the State of New York.

You are separately receiving an opinion from Bennett Jones LLP with respect to the corporate proceedings relating to the issuance of the Securities.

Based upon the foregoing and subject to the assumptions and qualifications set forth herein, we are of the opinion that the Units, Pre-funded Units, Warrants, Placement Agent Warrants and Pre-funded Warrants, when issued and sold by the Company and delivered by the Company in accordance with and in the manner described in the Prospectus and the Placement Agency Agreement, will constitute the valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, subject to applicable bankruptcy, insolvency, fraudulent conveyance, moratorium and similar laws affecting creditors' rights generally and equitable principles of general applicability.

We consent to the filing of this opinion as exhibit 5.2 to the Registration Statement, and we further consent to the use of our name under the caption "Legal Matters" in the Prospectus. In giving this consent, we do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission. This opinion letter is limited to the matters expressly set forth herein and no opinion is implied or may be inferred beyond the matters expressly so stated. This opinion letter is given as of the date hereof and we do not undertake any liability or responsibility to inform you of any change in circumstances occurring, or additional information becoming available to us, after the date hereof which might alter the opinions contained herein.

Very truly yours,

/s/ Sichenzia Ross Ference Carmel LLP

Sichenzia Ross Ference Carmel LLP

1185 AVENUE OF THE AMERICAS \| 31ST FLOOR \| NEW YORK, NY \| 10036<br>T (212) 930-9700 \| F (212) 930-9725 \| WWW.SRFC.LAW<br>

## Exhibit 23.1

**Exhibit 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in the Registration Statement on Form S-1-MEF filed pursuant to Rule 462(b) of the Securities Act of 1993, as amended, dated January 13, 2026, of our auditor's report dated October 15, 2025 with respect to the consolidated financial statements of BriaCell Therapeutics Corp and its subsidiaries as at July 31, 2025 and July 31, 2024 and for each of the years in the two year period ended July 31, 2025, as included in the Annual Report on Form 10-K of BriaCell Therapeutics Corp. for the year ended July 31, 2025, as filed with the United States Securities Exchange Commission.

We also consent the reference to our firm under the heading "Experts" in the registration statement.

/s/ MNP LLP

Chartered Professional Accountants

Licensed Public Accountants

January 13, 2026

Mississauga, Canada

## Ex-Filing

?xml version='1.0' encoding='ASCII'?

**Exhibit 107**

Calculation of Filing Fee Tables

**FORM S-1**

(Form Type)

**BRIACELL THERAPEUTICS CORP.**

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered Securities

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Security Type** | **Security Class Title** | **Fee Calculation Rule** | **Amount**<br> **Registered** | **Proposed<br> Maximum<br> Offering<br> Price Per<br> Share** | **Maximum Aggregate Offering Price(1)(2)** |  | **Fee Rate** | **Amount of Registration Fee** |
| **Fees to Be Paid** | Equity | Units consisting of (2) | 457(o) |  |  | $5000000 | (3) | $0.00013810 | $690.50 |
| **Fees to Be Paid** | Equity | (i) Common Shares, no par value |  |  |  | 0- | (4) |  | 0- |
| **Fees to Be Paid** | Equity | (ii) One Warrant to Purchase One Common Share |  |  |  | 0- | (4) |  |  |
| **Fees to Be Paid** | Equity | Common Shares Underlying Warrants |  |  |  | $6562500 | (7) | $0.00013810 | $906.28 |
| **Fees to Be Paid** | Equity | Pre-funded Units consisting of (5) |  |  |  | 0- | (3) |  |  |
| **Fees to Be Paid** | Equity | (i) Common Shares |  |  |  | 0- | (6) |  |  |
| **Fees to Be Paid** | Equity | (ii) Pre-Funded Warrants to Purchase Common Shares |  |  |  | 0- |  |  |  |
| **Fees to Be Paid** | Equity | Common Shares Underlying Pre-Funded Warrants |  |  |  |  |  |  |  |
| **Fees to Be Paid** | Equity | Placement Agent Warrants to Purchase Common Shares |  |  |  | 0 |  |  |  |
|  | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** |  | $11562500 |  |  | $1596.79 |
|  | **Total Fees Previously Paid** | **Total Fees Previously Paid** | **Total Fees Previously Paid** | **Total Fees Previously Paid** |  |  |  |  | $- |
|  | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** |  |  |  |  | $- |
|  | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** |  |  |  |  | $1596.79 |

---

(1) Represents
 only the additional dollar amount of securities being registered. Does not include the securities that the registrant previously
 registered on the registration statement on Form S-1 (File No. 333-292388).

(2) Each
 Common Unit consists of one common share and one warrant, each whole warrant exercisable for one common share.

(3) The
 proposed maximum aggregate offering price of Common Units proposed to be sold in the offering will be reduced on a dollar-for-dollar
 basis based on the offering price of any Pre-funded Units offered and sold in the offering, and the proposed maximum aggregate offering
 price of the Pre-funded Units to be sold in the offering will be reduced on a dollar-for-dollar basis based on the offering price
 of any Common Units sold in the offering. Accordingly, the proposed maximum aggregate offering price of the Common Units and Pre-funded
 Units (including the common shares issuable upon exercise of the Pre-funded warrants included in the Pre-funded Units), if any, is
 $5,000,000.

(4) Included
 in the price of the Common Units. No separate registration fee required pursuant to Rule 457(g) under the Securities Act of 1933,
 as amended.

(5) Each
 Pre-funded Unit consists of one Pre-funded warrant to purchase one common share and one warrant to purchase one common share.

(6) Included
 in the price of the Pre-funded Units. No separate registration fee required pursuant to Rule 457(g) under the Securities Act of 1933,
 as amended.

(7) As
 estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(g) under the Securities Act, the proposed
 maximum aggregate offering price of the common shares underlying the warrants included in the Common Units and the Pre-funded Units
 includes the common shares issuable upon exercise of the placement agent's warrants.

N/A